BioLife Solutions (BLFS) investor relations material

Strategic focus and market positioning

• Leading provider of biopreservation and cell processing tools for cell-based therapies, with a 65% gross margin and 29% organic revenue growth in FY 2025.

• Refocused portfolio on cell processing tools, divesting storage, services, and freezer businesses to drive higher growth and profitability.

• Products specified in over 950 global cell-based therapy trials and used in ~90% of commercially relevant, FDA-approved cell-based therapies.

• Maintains a significant competitive moat due to high switching costs and mission-critical product roles.

• Positioned as a pure-play provider in a cell-based therapy market expected to grow over 20% annually through 2030.

Product platforms and differentiation

• Core products include CryoStor® (cryopreservation media), HypoThermosol® (hypothermic media), hPL solutions, CellSeal® vials, Signata (automated fill & finish), and ThawSTAR® (automated thawing).

• Biopreservation media deliver consistent, high post-thaw cell viability and are widely adopted in clinical and commercial programs.

• Cell processing tools enhance workflow efficiency, reduce contamination risk, and support robust cell expansion.

• Increasing multi-product specification in early-stage trials supports sustained growth.

Financial performance and outlook

• FY 2025 revenue reached $96M with a 65% gross margin and 26% adjusted EBITDA margin.

• Adjusted EBITDA for FY 2025 was $25M, with a margin of 26%.

• 17–20% revenue growth expected for FY 2026, with positive GAAP net income and continued EBITDA margin expansion.

• Fixed cost leverage, pricing, and increased multi-product penetration are key growth drivers.